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Abstract 
Background: Lichen sclerosus (LS) is a chronic, inflammatory tissue disease that most commonly affects 
adult women. The current treatment is long-term topical steroids. Platelet-rich plasma (PRP) has gained 
much attention as a treatment for multiple tissue disorders due to its rejuvenating qualities. The purpose 
of this review is to investigate PRP’s effectiveness on treating lichen sclerosus in adult women. 
Methods: An Exhaustive literature search was performed using MEDLINE, TRIP, and Google Scholar and 
the following search terms were used “vaginal atrophy,” "lichen sclerosus," "vulvovaginal atrophy," "lichen 
simplex chronicus," "platelet." All studies included were within the last 5 years and of English language. 
Results: The search yielded 3 articles that met criteria. All 3 articles were case studies. There was an 
overall trend in all 3 articles that PRP treatment improves the clinical course of LS as well as improves 
patients’ symptoms. However, the overall quality of the articles is very low due to limitations and high risk 
of bias (see Table 1). Future studies are needed to yield a higher grade of research for more definitive 
conclusions on this topic. 
Conclusion: While the studies that investigated the effects of PRP treatment on adult women with LS had 
an overall positive trend, more research is needed due to the very low quality of evidence. Randomized 
controlled trials with larger sample sizes, blinding, and adequate follow-up times are needed to better 
determine the effects of PRP on LS in adult women. Only then will medical professionals have a better 
idea if PRP can replace topical corticosteroids as the gold standard for treatment. 
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Abstract 
Background: Lichen sclerosus (LS) is a chronic, inflammatory tissue 
disease that most commonly affects adult women.  The current 
treatment is long-term topical steroids.  Platelet-rich plasma (PRP) has 
gained much attention as a treatment for multiple tissue disorders due 
to its rejuvenating qualities.  The purpose of this review is to 
investigate PRP’s effectiveness on treating lichen sclerosus in adult 
women.   
Methods: An Exhaustive literature search was performed using 
MEDLINE, TRIP, and Google Scholar and the following search terms 
were used “vaginal atrophy,” "lichen sclerosus," "vulvovaginal 
atrophy," "lichen simplex chronicus," "platelet."  All studies included 
were within the last 5 years and of English language. 
Results: The search yielded 3 articles that met criteria.  All 3 articles 
were case studies.  There was an overall trend in all 3 articles that PRP 
treatment improves the clinical course of LS as well as improves 
patients’ symptoms.  However, the overall quality of the articles is 
very low due to limitations and high risk of bias (see Table 1).  Future 
studies are needed to yield a higher grade of research for more 
definitive conclusions on this topic. 
Conclusion: While the studies that investigated the effects of PRP 
treatment on adult women with LS had an overall positive trend, more 
research is needed due to the very low quality of evidence.  
Randomized controlled trials with larger sample sizes, blinding, and 
adequate follow-up times are needed to better determine the effects of 
PRP on LS in adult women. Only then will medical professionals have a 
better idea if PRP can replace topical corticosteroids as the gold 
standard for treatment.    
Keywords: Lichen sclerosus, vaginal atrophy, vulvovaginal atrophy, 
lichen simplex chronicus, platelet. 
- 4 - Revised 07Dec2009 
Acknowledgements 
[Redacted] 
 - 5 - Revised 07Dec2009 
Table of Contents 
 
Biography ........................................................................................................................ 2 
Abstract ............................................................................................................................ 3 
Acknowledgements ...................................................................................................... 4 
Table of Contents ......................................................................................................... 5 
List of Tables .................................................................................................................. 6 
List of Abbreviations ................................................................................................... 6 
BACKGROUND ........................................................................................................... 7 
METHODS .................................................................................................................. 10 
RESULTS .................................................................................................................... 11 
DISCUSSION ............................................................................................................ 18 
CONCLUSION ........................................................................................................... 21 
References .................................................................................................................... 22 
Table I: Quality Assessment of Reviewed Articles ........................................ 24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 6 - Revised 07Dec2009 
 
List of Tables  
 
Table 1:       Quality Assessment of Reviewed Studies  
 
 
 
List of Abbreviations 
 
FSFI  Female Sexual Function Index 
ICIQ-VS     International Consultation on Incontinence Questionnaire –  
  Vaginal Symptoms                                                               
LS  Lichen Sclerosus 
PRP  Platelet-rich Plasma 
SCC   Squamous Cell Carcinoma 
   
 
 
 
 
 - 7 - Revised 07Dec2009 
Determining if Platelet-rich Plasma is an 
Effective Treatment of Lichen Sclerosus in Adult 
Women 
BACKGROUND 
Lichen sclerosus (LS) is a chronic, immune-mediated skin 
disease that typically affects the anogenital region.1  While LS can 
affect anyone at any age, most cases occur in both prepubertal and 
postmenopausal women.1,2  While the exact etiology and pathogenesis 
is unknown, trauma, chronic irritation, and hormonal changes all seem 
to contribute as potential causative factors.  There is also evidence 
showing that pre-existing autoimmune-related diseases and/or a 
family history of LS may also contribute to one developing LS.3,4  LS 
may be asymptomatic in some or may cause unpleasant complications 
such as erosions, atrophy and scarring.  These complications are a 
result from the inflammation the disease causes and may lead to 
altered fibroblast function and fibrosis of the upper dermis.  As the 
disease progresses, scarring may increase, leading to a loss of the 
labia minora, sealing of the clitoral hood, and burying of the clitoris.5  
Many women also experience pruritis, dyspareunia, dysuria and genital 
bleeding which can decrease one’s quality of life, especially sexual 
satisfaction.  These negative side effects are further compounded by 
the lack of estrogen in postmenopausal women.5  Furthermore, LS has 
been known to develop into squamous cell carcinoma (SCC).  “There is 
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a 4% lifetime risk of developing SCC among LS sufferers6 and 
histopathological examination of vulva SCC cases shows that over 60% 
have a background of LS.”7 
Women dealing with LS and the negative side effects that 
accompany the disease are faced with not only physical ailments, but 
emotional and psychological issues as well that require extensive 
counseling and support.  Currently, there is no cure for LS, though 
some few patients have been known to experience spontaneous 
remission.1  The most common existing treatment is topical steroids 
and these focus merely on symptom relief.  Furthermore, they are 
used long-term and consequently, compliance rates among many 
patients are low.2  There are no universally accepted treatment 
recommendations based on type and duration of steroid use, however, 
some studies show success with “Clobetasol propionate (0.05%) twice 
daily for 2 to 3 months with gradual dose lowering.”8  Unfortunately, 
topical corticosteroids have negative side-effects of their own, 
especially in long-term use.  These can include cutaneous atrophy, 
adrenal suppression, hypopigmentation and contact sensitivity such as 
burning, itching, dryness, flaking and maceration.  Furthermore, once 
the patient stops using the topical steroid, their symptoms and disease 
progression are likely to return and potentially worsen.1 
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  Platelet-rich plasma (PRP) is an “autologous preparation of 
platelets in concentrated plasma.”9  It has gained much attention in 
the medical field due to its regenerating qualities.  PRP contains an 
abundant amount of growth factors, including platelet-derived growth 
factor (PDGF), transforming growth factor (TGF), vascular endothelial 
growth factor (VEGF), and insulin-like growth factor (IGF).9  These 
factors are pertinent in stem cell migration, differentiation and 
proliferation.2  Some hypothesize that PRP may encourage collagen 
synthesis and other matrix components in the skin by stimulating 
fibroblasts9 which are responsible for neovascularization and 
deposition of new extracellular matrix.10,11 PRP treatment has already 
been successful clinically in tissue regeneration, reconstructive and 
plastic operations, and surgery, including wound hemostasis, wound 
sealing, augmentation of bone grafts periodontics, and treatment of 
tendonitis.12–14  
  LS could be the next tissue disease that benefits from PRP 
treatment.  This review’s purpose is to look at studies that used PRP 
injections as treatment for adult women that suffered from topical 
steroid-resistant LS in hopes that, someday, PRP could become the 
main treatment for LS.          
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METHODS 
An Exhaustive literature search was performed using MEDLINE, 
TRIP, and Google Scholar and the following search terms were used; 
("vaginal atrophy" OR "lichen sclerosus" OR "vulvovaginal atrophy" OR 
"lichen simplex chronicus") AND "platelet."  Eligibility criteria included 
studies that used adult women as participants with lichen sclerosus 
and consented to receive PRP as treatment of their disease.  All 
studies included were within the last 5 years and of English language. 
Studies were assessed for quality using GRADE criteria.15 
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RESULTS 
An initial search of MEDLINE using the keywords listed above 
yielded 11 articles.  These were reviewed and 3 articles2,5,16 met 
eligibility criteria.  All 3 of the studies were case studies.  A search of 
TRIP using the same keywords yielded 19 articles for review.  None of 
the 19 articles met eligibility criteria.  Finally, a search of Google 
Scholar was performed using the same keywords and 739 results 
appeared.  The first 10 pages of articles were reviewed, and 3 articles 
met eligibility requirements; the same articles that were originally 
found with MEDLINE.  In conclusion, this review analyzes a total of 3 
articles. 
Behnia-Willison F, Pour NR, Mohamadi B, et al (2016) 
In this case series,5 28 adult women between the ages of 22 to 
88 years (M=60) who attended FBW Gynaecology Plus from 2013 to 
2016 were enrolled.  Twenty-six out of the 28 had confirmed LS on 
biopsy, yet colposcopy suggested the existence of LS in all 28 patients.  
All patients’ symptoms were reported as unresponsive to steroids and 
patients were instructed to cease use of steroids during the study’s 
course.5   
Patients had their own blood drawn (10mL) and centrifuged 
(Regens Lab, New York, N.Y.) on site and injected after being given 
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local anesthesia.  The PRP was injected with a 27 G needle to any 
affected areas of the women’s external genitalia, including the labia 
majora, labia minora, clitoris and clitoral hood.  The author describes 
the injection technique as using “a fanning motion to break the scar 
and fibrotic tissue” and then to inject the PRP in a retrograde fashion 
into the tissue.  Patients received a total of 4 PRP treatments; 3 PRP 
treatments with 4 to 6 weeks in-between each treatment and then 1 
final treatment at 12 months.  They were verbally interviewed about 
their symptoms after each treatment and lesions were evaluated via 
colposcopy.  Patients found to have vulval intraepithelial neoplasia 
(n=2) were excluded from the study.  A verbal scale from 0 to 10 was 
used after each treatment to measure post-treatment pain and 
patients were asked to complete the Australian Pelvic Floor 
Questionnaire 24 at baseline and at 2 to 3 months after the final PRP 
treatment.  This questionnaire measured urinary incontinence, general 
bladder function, prolapse, and sexual function.  “Changes in lesion 
size, symptoms, and need for topical steroid use were compared from 
pre- to post-treatment using the Wilcoxon signed-rank test” and 
“statistical analyses were performed using SPSS Statistics version 21.0 
(IBM, Chicago, Ill.).”5   
Twenty-five of the 28 participants exhibited clinical improvement 
in the size of their lesions and of those, 8 of the participants’ lesions 
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disappeared completely.  “A Wilcoxon signed-rank test indicated that 
there was a statistically significant decrease in the number of patients 
with lesions after the PRP treatment (Z=-4.562; P<0.001).”  Before 
treatments, patients complained of severe itch, soreness, discomfort, 
and/or dyspareunia.  Fifteen of the 28 participants were symptom free 
after the last treatment at 12 months or more.  “A Wilcoxon signed-
rank test showed a statistically significant decrease in the presence of 
symptoms after treatment (Z=-4.768; P<0.001).” After the final 
treatment of PRP, 82.1% of the patients (n=23) no longer needed to 
use steroids, and the remaining 17.9% (n=5) reported using them 
intermittently. “A Wilcoxon signed-rank test showed a statistically 
significant decrease in steroid use after treatment with PRP (Z=-
4.963; P<.001).”  The authors noted a trend of declining responses to 
the Australian Pelvic Floor Questionnaire when comparing pre- and 
post-treatment scores, however, these were not statistically 
significant.  There were zero cases of infection, bleeding, hematoma or 
other adverse outcomes.  Patients did report minimal to moderate pain 
during the 24 hours after the procedure: 26 patients (92.9%) reported 
pain scores of 2 to 3, and the remaining 2 patients reported scores of 
5 and 7.5 
 
 
 
 
 - 14 - Revised 07Dec2009 
Franic D, Iternička Z, Franić-Ivanišević M (2018) 
 
The second study is a case study2 of a 38-year-old 
premenopausal woman.  She complained of itching, burning, stiffness 
and pain in her external genital area, and reported impaired sexual 
activity related to a narrow and thick vaginal introitus.  Her condition 
was refractory to corticosteroid ointment as well as moisturization with 
emollients.  She reported using pH-neutral soaps as well as 2% 
testosterone gel, all to no avail.  To measure her symptoms, she was 
asked to complete the validated International Consultation on 
Incontinence Questionnaire – Vaginal Symptoms (ICIQ-VS) instrument 
rating scale.  Her total vaginal symptoms score was 42, her total 
sexual symptoms score was 42, and her score for quality of life as 
affected by LS was 8.  She also completed the Female Sexual Function 
Index (FSFI) before and after PRP treatment.  This measured desire, 
arousal, lubrication, orgasm, satisfaction and pain with an initial score 
of 3.6.  Her pretreatment biopsy showed fully developed LS, with 
epidermal atrophy, hyperkeratosis, subepidermal edema with 
hyalinization and dilated vessels as well as sparse lymphocytic 
infiltrates beneath.2 
  The patient’s PRP treatment was prepared from autologous blood 
from a venous sample using Regenkit®.  Anesthetic gel was applied to 
the vulva and left for 10 minutes before 4mL of PRP was injected 
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subdermally with a 23 G needle.  This same therapy was repeated two 
months later, in the same fashion, with the exception that two tubes of 
Cellular Matrix Regenkit were used to attain 8mL of PRP.  The patient 
returned two months after the second treatment for follow-up 
measurements.  Her posttreatment biopsy showed a nearly normal 
epidermis with restored upper dermal cellularity.  She reported feeling 
comfortable, symptom-free, and stated that her sex drive had 
returned, and her quality of life had increased significantly.  Her 
posttreatment ICIQ-VS total score improved to 7; her sexual matters 
score improved to 0; and her quality of life score improved to 0.  Her 
full-scale FSFI score improved to 32.6.2    
  The author concludes that this case study shows PRP may be a 
“promising new treatment for female genital LS, as it promotes 
regeneration and leads to cessation of symptoms, which is generally 
not achieved with the standard current therapy options.”2 
Goldstein AT, King M, Runels C, Gloth M, Pfau R (2017) 
 
The final study was a pilot case series16 that included 15 adult 
women with biopsy-proven vulvar lichen sclerosus.  Each participant 
received 2 separate treatments of PRP with 6 weeks in-between 
treatments.  Each treatment was comprised of 5mL of autologous PRP, 
using the Magellan Autologous Platelet Separator System, Arteriocyte 
Medical Systems.  The PRP was injected subdermally and 
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intradermally.  Post-treatment biopsies were taken 6 weeks after the 
second treatment.  Patients were prohibited from using additional 
medications while the study took place.16 
The primary efficacy variable that the study looked at was 
change in inflammation between the pre- and post-treatment biopsies.  
These were measured by 2 masked dermatopathologists.  Secondary 
endpoints were changes from baseline in pruritis and vulvar burning 
using visual analogue scales (VAS) and change in Investigator’s Global 
Assessment (IGA) of the severity of the disease, using 0 to 3 scale.  
Out of the 15 original participants, 12 completed the entire study; 2 
patients were lost to follow-up before the second PRP treatment and 
one refused to have the post-treatment biopsy performed.  Results 
from the biopsies of the 12 remaining participants showed that 7 had 
decreased inflammation, 3 had no change, and 2 had a “minimal” 
increase in inflammation.  A repeated measures ANOVA showed the 
results were statistically significant (p=0.024) and a paired-sample t-
test comparing the pre- and post-treatment IGA scores showed a 
statistically significant difference as well: pre-treatment (M=2.67, 
SD=0.49) and post-treatment (M=1.83, SD=0.83); t(11)=3.4578, 
p=0.0054.  The results showed that changes in subjective VAS scores 
for pruritis and burning were not statistically significant and no 
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adverse side effects were reported during the study with the exception 
of transient discomfort and bruising at biopsy and injection sites.16    
 The authors conclude, “the statistically significant results suggest 
that PRP decreased histopathologic inflammation in women with VLS 
without potential side effects associated with topical or systemic 
immunomodulators.”16 
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DISCUSSION 
The 3 studies2,5,16 show an overall positive trend of injecting PRP 
as treatment for LS in adult women.  The studies’ purposes were to 
find an alternate treatment for women whose condition failed on 
topical corticosteroids.  In all 3 studies, the majority of women found 
that their lesions improved or even disappeared completely after the 
PRP treatments.  Additionally, most found a decrease in their 
accompanying symptoms and therefore an increase in their quality of 
life.  The studies also found minimal side effects with PRP treatment, 
indicating that the safety of this treatment may be superior over long-
term use of corticosteroids.  The only side effects reported were 
minimal pain and bruising at sites of injections and biopsies and 
Golstein et al’s study found a “minimal” increase of inflammation on 
two of the participants’ post-treatment biopsies.2,5,16  Behnia-Willison 
et al notes that “the PRP procedure is minimally invasive and safe and 
may be performed in an office setting under local anesthesia.”5 
While the safety of PRP treatment was proven in these 
studies,2,5,16 more research is required on this topic due to the many 
limitations and risk of bias these studies included.  The risk of bias was 
great in all of the studies since they were not blinded.  The Goldstein 
et al study16 does mention a form of blinding to determine the extent 
of the inflammation on the pre- and post-treatment biopsies as 2 
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masked dermatopathologists were used.  Also, all of the studies were 
case studies/series, indicating a very low quality of evidence due to 
their small sample sizes and lack of comparing the therapy to a control 
group (see Table 1).  Behnia-Willison et al5 even notes, “it is 
conceivable that the observed improvements in LS symptoms after 
PRP treatment were partially or wholly due to the tissue needling 
involved in the PRP injection process rather than to a simple effect of 
the PRP in and of itself.”  Another flaw in these studies was that there 
was not sufficient follow-up time with participants.  Pugliese et al1 
noted in their review, corticosteroids may help manage LS when 
applied in a consistent manner, but when they are stopped, the 
patient’s symptoms are very likely to return.  None of the studies 
continued to follow-up with participants after the final PRP treatment.  
Therefore, it is unknown whether or not patients would need to 
continue to return to clinic for maintenance PRP treatments to keep 
their LS under control or from returning.  Another area of weakness in 
the studies is their variability in methods.  Each study used a different 
amount of PRP in their injections, different time between treatments, 
and even different numbers of treatments.   
Due to the very low quality of evidence of all 3 of the 
studies,2,5,16 more research is needed before PRP treatment becomes 
the gold standard of treatment in LS in adult women.  Randomized 
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control trials should be developed and executed with ample population 
sizes, randomization techniques, double-blinding, control groups and 
adequate follow-up time.  Behnia-Willison et al5 states in their study 
that they “intend to conduct a double-blind RCT in which one group is 
randomized to a saline injection, with a second group randomized to 
PRP treatment.”  Goldstein is listed as a principle investigator for a 
“randomized single-blind placebo controlled trial to evaluate the 
efficacy and safety of autologous Platelet-rich Plasma (PRP) for the 
treatment of vulvar lichen sclerosus” which just finished up June 
2018.17  
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CONCLUSION 
PRP treatment is gaining popularity in tissue diseases due to its 
regenerative qualities and lichen sclerosus is one of the next diseases 
that may benefit from it.  The studies in this review support the idea 
that PRP could be an effective treatment and possibly replace topical 
steroids as the gold standard in treatment of LS in adult women, 
however, more research is needed due to these studies’ very low 
quality of evidence.  Good news is that there are promising studies 
currently taking place that will likely bring forth higher quality data in 
an effort to prove PRP is an effective treatment for adult women with 
LS.   
 
 - 22 - Revised 07Dec2009 
References 
 
1.  Pugliese JM, Morey AF, Peterson AC. Lichen Sclerosus: Review of the Literature 
and Current Recommendations for Management. J Urol. 2007;178(6):2268-2276. 
doi:10.1016/j.juro.2007.08.024 
2.  Franic D, Iternička Z, Franić-Ivanišević M. Platelet-rich plasma (PRP) for the 
treatment of vulvar lichen sclerosus in a premenopausal woman: A case report. Case 
Rep Womens Health. 2018;18:e00062. doi:10.1016/j.crwh.2018.e00062 
3.  Kirtschig G. Lichen Sclerosus-Presentation, Diagnosis and Management. Dtsch 
Arzteblatt Int. 2016;113(19):337-343. doi:10.3238/arztebl.2016.0337 
4.  Sherman V, McPherson T, Baldo M, Salim A, Gao XH, Wojnarowska F. The high 
rate of familial lichen sclerosus suggests a genetic contribution: an observational 
cohort study. J Eur Acad Dermatol Venereol JEADV. 2010;24(9):1031-1034. 
doi:10.1111/j.1468-3083.2010.03572.x 
5.  Behnia-Willison F, Pour NR, Mohamadi B, et al. Use of Platelet-rich Plasma for 
Vulvovaginal Autoimmune Conditions Like Lichen Sclerosus. Plast Reconstr Surg 
Glob Open. 2016;4(11). doi:10.1097/GOX.0000000000001124 
6.  Wallace HJ. Lichen sclerosus et atrophicus. Trans St Johns Hosp Dermatol Soc. 
1971;57(1):9-30. 
7.  Neill SM, Tatnall FM, Cox NH, British Association of Dermatologists. Guidelines 
for the management of lichen sclerosus. Br J Dermatol. 2002;147(4):640-649. 
8.  Val I, Almeida G. An overview of lichen sclerosus. Clin Obstet Gynecol. 
2005;48(4):808-817. 
9.  Kim DH, Je YJ, Kim CD, et al. Can Platelet-rich Plasma Be Used for Skin 
Rejuvenation? Evaluation of Effects of Platelet-rich Plasma on Human Dermal 
Fibroblast. Ann Dermatol. 2011;23(4):424-431. doi:10.5021/ad.2011.23.4.424 
10.  Rappl LM. Effect of platelet rich plasma gel in a physiologically relevant platelet 
concentration on wounds in persons with spinal cord injury. Int Wound J. 
2011;8(2):187-195. doi:10.1111/j.1742-481X.2011.00770.x 
11.  Graziani F, Ivanovski S, Cei S, Ducci F, Tonetti M, Gabriele M. The in vitro effect 
of different PRP concentrations on osteoblasts and fibroblasts. Clin Oral Implants 
Res. 2006;17(2):212-219. doi:10.1111/j.1600-0501.2005.01203.x 
12.  Jeon YR, Kang EH, Yang CE, Yun IS, Lee WJ, Lew DH. The effect of platelet-rich 
plasma on composite graft survival. Plast Reconstr Surg. 2014;134(2):239-246. 
doi:10.1097/PRS.0000000000000392 
 - 23 - Revised 07Dec2009 
13.  Salcido RS. Autologous platelet-rich plasma in chronic wounds. Adv Skin Wound 
Care. 2013;26(6):248. doi:10.1097/01.ASW.0000430666.20897.c0 
14.  Harris NL, Huffer WE, von Stade E, Larson AI, Phinney S, Purnell ML. The effect 
of platelet-rich plasma on normal soft tissues in the rabbit. J Bone Joint Surg Am. 
2012;94(9):786-793. doi:10.2106/JBJS.J.00984 
15.  GRADE home. http://www.gradeworkinggroup.org/. Accessed January 26, 2019. 
16.  Goldstein AT, King M, Runels C, Gloth M, Pfau R. Intradermal injection of 
autologous platelet-rich plasma for the treatment of vulvar lichen sclerosus. J Am 
Acad Dermatol. 2017;76(1):158-160. doi:10.1016/j.jaad.2016.07.037 
17.  Goldstein AT, Mitchell L, Govind V, Heller D. A randomized double-blind 
placebo-controlled trial of autologous platelet-rich plasma intradermal injections for 
the treatment of vulvar lichen sclerosus. J Am Acad Dermatol. 2019;0(0). 
doi:10.1016/j.jaad.2018.12.060 
 
 
 
 
 - 24 - Revised 07Dec2009 
 
 
 
Study Study 
Design 
Downgrade Criteria Upgrade 
Criteria 
Quality 
Limitations Indirectness Inconsistency Imprecision Publication 
bias 
Behnia-Willison et 
al5 
Case 
Series 
Seriousa,b,c Not Serious Not Serious Seriousd Unlikely None Very Low 
Franic et al2 Case 
Study 
Seriousa,b,c, Not Serious Not Serious Seriousd Unlikely None Very Low 
Goldstein et al16 Case 
Series 
Seriousa,b,c, Not Serious Not Serious Seriousd Unlikely None Very Low 
a
Lack of blinding and control group 
b
Use of subjective questionnaire to determine outcomes 
c
Inadequate follow-up time 
d
Small sample size 
 
 
 
 
 
 
 
 
 
 
 
 
Table I: Quality Assessment of Reviewed Articles 
